Table 5.
Estimation of the difference in the enzyme activities between the intervention groups evaluated at week 8 of the study.
| Variable | Enriched Yogurt vs. Control | Plain Yogurt vs. Control | Enriched vs. Plain Yogurt |
|---|---|---|---|
| PAF-AH (pmol/mg/min) | −4.88 (−11.30, 1.54) | −7.48 (−20.80, 5.85) | −1.89 (−12.30, 8.53) |
| LpPLA2 (nmol/mL/min) | −0.93 (−1.90, 0.03) | −0.72 (−2.46, 1.02) | −1.45 (−3.69, 0.79) |
| PAF-CPT (pmol/mg/min) | −10.58 (−20.81, −0.35) | −19.15 (−38.15, −0.14) | 5.0 (−10.97, 20.97) |
| Lyso-PAF ATC (pmol/mg/min) | −2.68 (−11.83, 6.48) | −9.19 (−34.47, 16.10) | −3.48 (−23.19, 16.24) |
| Lyso-PAF ATE (pmol/mg/min) | 1.93 (−0.55, 4.42) | 0.93 (−5.05, 6.91) | −0.02 (−6.43, 6.39) |
| LpPLA2-to-LDL ratio | −0.005 (−0.015, 0.005) | 0.0001 (−0.017, 0.017) | −0.019 (−0.034, −0.003) |
Median regression was performed for each pair of intervention groups; adjustments were made for sex and enzyme variable values at baseline. Results are presented as difference in medians (95% confidence interval of the difference) between intervention groups. Significance (α) level was set to 0.05. BMI: body mass index; LDL: low-density lipoprotein; LpPLA2: lipoprotein-associated phospholipase A2; Lyso-PAF ATC: lyso-platelet-activating factor acetyltransferase in the presence of Ca2+; Lyso-PAF ATE: lyso-platelet-activating factor acetyltransferase in the presence of EDTA; PAF-AH: platelet-activating acetyl-hydrolase; PAF-CPT: platelet-activating factor-cholinephosphotransferase.